Ashland injectable pharmaceutical excipient accepted into fda novel excipient review pilot program

Wilmington, del., oct. 31, 2022 (globe newswire) -- ashland inc. (nyse: ash) today announced the united states food and drug administration (fda) center for drug evaluation and research office of new drugs has accepted ashland viatel™ bioresorbable mpeg-pdlla pharmaceutical excipient in the review cycle of the fda novel excipient review pilot program.
ASH Ratings Summary
ASH Quant Ranking